Bisphosphonate. Bisphosphonate BP. Starck BP. BP Bisphosphonate Related Osteonecrosis of the Jaw : BRONJ BP ONJ BP P O P P C P + BRONJ BP BP BRONJ

Μέγεθος: px

Εμφάνιση ξεκινά από τη σελίδα:

Download "Bisphosphonate. Bisphosphonate BP. Starck BP. BP Bisphosphonate Related Osteonecrosis of the Jaw : BRONJ BP ONJ BP P O P P C P + BRONJ BP BP BRONJ"

Ζώσιμος Αντωνοπούλου
5 χρόνια πριν
Προβολές:

1 Bisphosphonate Bisphosphonate BP Starck BP BP Bisphosphonate Related Osteonecrosis of the Jaw : BRONJ BP ONJ BP BRONJ BP BP BRONJ BRONJ BP BP BP BP BP BRONJ BP BP P O P P C P + BP Dent. J. Iwate Med. Univ

2 + Bisphophonates,**.**, + + +* +, -/ + +** +5***, -/ + +** +5*** /,./ +5*** +*5*** -,./ +5*** +*5*** 3*. +**, +*. +** +5***, +*. +** +5*** +*,. +** +5*** -. +/ +*5*** - + BP BP BP + BP R + R, BP BP BP + + BP

3 Bisphosphonate BRONJ BRONJ BP BP BP BRONJ BRONJ BRONJ BRONJ BRONJ X X BRONJ Novartis Home Page BRONJ Novartis BRONJ. Hoff MD Andeson Cancer Center BP, BRONJ BRONJ BRONJ.. Wang... Zervas BRONJ

4 , Grade + A *4/ + B *4/, A *4/*433, B *4/*433 - A +4*,4* - B +4*,4*. A. B BP BP BP BRONJ BP BRONJ Dunstan... BP BRONJ. BP. BRONJ.. BP BRONJ BP BP BP Mehrotra & Ruggiero BP BRONJ BP BRONJ Novartis, BRONJ - BRONJ HBO Freiberger BRONJ HBO

5 Bisphosphonate - BRONJ BRONJ Risk category Stage Stage / Stage +. BP + - X, X -.

6 X X X CT MRI / Gy X 0 1 BP HBO HBO

7 Bisphosphonate 2,, X BP BP BRONJ BRONJ BP BRONJ BP BRONJ BP BRONJ BP BP BP BP. BP BP BP BRONJ BP BRONJ BRONJ

8 BP + Starck, W.J. and Epker, B.N. : Failure of osseointegrated dental implants after diphosphonate therapy for osteoporosis : a case report. Int. J. Oral Maxillofac. Implants, +* : 1.-12, +33/., Wang, E.P., Kaban, L.B., Strewler, G.J., Raje, N. and Troulis, M.J. : Incidence of osteonecrosis of the jaw in patients with multiple myeloma and breast or prostate cancer on intravenous bisphosphonate therapy. J. Oral Maxillofac. Surg. 0+ : ++*.-++*1,,**-. - Marx, R.E. : Pamidronate (Aredia) and Zoledronate (Zometa) induced avascular necrosis of the jaws : A growing epidemic. J. Oral Maxillofac. Surg. 0+ : +++/-+++2,,**-.. Migliorati, C.A. : Bisphosphonates and bone necrosis. J. Clin. Oncol.,+ :.,/--.,/.,,**-. / + /, : ,,** /- :,2--,,,**1. 1 /-: /3.-0*,,,** :,30-,32,,** : + -+*,,**1. +* Mehrotra, B. and Ruggiero, S., : Bisphosphonate complications including osteonecrosis of the jaw. Hematology,,**0 : -/0--0*,,**0. ++ Advisory task force on bisphosphonate- related osteonecrosis of the jaws : American association of oral and maxillofacial surgeons position paper on bisphosphonate-related oasetonecrosis of the jaws. J. Oral Maxillofac. Surg. 0/ : /,,**1. +, Ruggiero, S.L., Mehrotra, B., Rosenberg, T.J. and Engroff, S.L. : Osteonecrosis of the jaws associated with the use of bisphosphonates : a review of 0- cases. J. Oral Maxillofac. Surg. 0, : /,1-/-.,,**.. +- Gutta, R. and Louis, P.J. : Bisphosphonates and osteonecrosis of the jaws : Science and rationale. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod. +*. : ,,**1. +. American Dental Association : Osteonecrosis of the jaw. Available at : http : // prof/resources/topics/osteonecrosis.asp +/ Pucell, P.M. and Boyd, I.W. : Bisphosphonate and osteonecrosis of the jaw. Med. J. Australia, +2,: ,,**/. +0 Novartis Phamaceuticals Canada Inc. : Updated safety : Possible relationship of Aredia (pamidronate disodium) and/or Zometa (zoledronic acid) with osteonecrosis of the jaw. Available at : http : // medeff/advisories-avis/prof/,**./aredia zom hpc cps e.html +1 Hoff, A.O., Toth, B.B., Altundag, K., Guarneri, V., Adamus, A., Nooka, A.K., Sayegh, G.G., Johnson, M.M., Gagel, R.F. and Hortobagyi, G.N. : Osteonecrosis of the jaw inpatients receiving intravenous bisphosphonate therapy.,**0 ASCO anuual meeting proceedings (postmeeting edition). J. Clinic. Oncology,,. : 2/,2,,**0. +2 Zervas, K., Verrou, E., Teleioudis, Z., Vahtsevanos, K., Banti, K., Mihou, D., Krikelis, D. and Terpos, E. : Incident, risk factors and management of osteonecrosis of the jaw in patients with multiple myeloma : a single-centre experience in -*- patients. Br. J. Haematol. +-. : 0,*-0,-,,**0. +3 Mavrokokki, T., Cheng, A., Stein, B. and Goss, A. : Nature and frequency of bisphosphonateassociated osteonecrosis of the jaws in Australia. J. Oral Maxillofac. Surg. 0/ :.+/-.,-,,**1.,* Dunstan, C.R., Felsenberg, D. and Seibel, M.J. : Therapy insight : the risk and benefits of bisphosphonates for the treatment of tumor-induced bone disease. Nat. Clin. Pract. Oncol.. :.,-//,,**1.,+ Novartis : Updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients : May,**0. Available at : http : // uct/zom/te/te arezom*0*1 a.html,, Freiberger, J.J., Padilla-Burgos, R., Chhoeeu, A. H., Kraft, K.H., Boneta, O., Moon, R.E. and Piantadosi, C.A. : Hyperbaric oxygen treatment and bisphosphonate-induced osteonecrosis of the jaw : a case siries. J. Oral Maxillofac. Sung. 0/ : +-,+-+-,1,,**1.,- Harper, R.P. and Fung, E.F. : Resolution of bisphosphonate-associated osteonecrosis of the mandible : Possible application for intermittent low-dose parathyroid hormone [rhptm ( + --.)]. J. Oral Maxillofac. Surg. 0/ : /1--/2*,,**1.

Σχετικά έγγραφα

Οστεονέκρωση γνάθων aπό λήψη διφωσφονικών: Νέα δεδομένα και αντιμετώπιση

Θέμα Ειδικού Ενδιαφέροντος EΛΛΗΝΙΚΗ ΡΕΥΜΑΤΟΛΟΓΙΑ 2008,19(1):74-80 Οστεονέκρωση γνάθων aπό λήψη διφωσφονικών: Νέα δεδομένα και αντιμετώπιση Γ. Λάσκαρης 1 Ε. Γκάγκαρη 2 Περίληψη Η εργασία αυτή αναφέρεται